SYNTIS BIO
Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability.
SYNTIS BIO
Social Links:
Industry:
Health Care Medical Therapeutics
Founded:
2022-01-01
Address:
Milton, Massachusetts, United States
Country:
United States
Website Url:
http://www.syntis.bio
Total Employee:
11+
Status:
Active
Total Funding:
15.37 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon WordPress Sitelinks Search Box Wordpress Plugins Yoast WordPress SEO Plugin Yoast Plugins Yoast SEO Premium
Similar Organizations
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Mediar Therapeutics
Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis.
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Satsuma Pharmaceuticals
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Employees Featured
Founder
Investors List
Safar Partners
Safar Partners investment in Seed Round - Syntis Bio
Bold Capital Partners
Bold Capital Partners investment in Seed Round - Syntis Bio
Touchdown Ventures
Touchdown Ventures investment in Seed Round - Syntis Bio
Colorcon Ventures
Colorcon Ventures investment in Seed Round - Syntis Bio
Portal Innovations
Portal Innovations investment in Seed Round - Syntis Bio
Official Site Inspections
http://www.syntis.bio Semrush global rank: 7.95 M Semrush visits lastest month: 736
- Host name: 151.101.66.159
- IP address: 151.101.66.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Syntis Bio"
About - Syntis
Dr. Robert Langer, Co-founder of Syntis Bio and a board director, is one of eight Institute Professors at MIT, which is the highest honor awarded to a faculty member. He has written over 1,500 articles that have been cited over 422,000 …See details»
Syntis Bio - Crunchbase Company Profile & Funding
Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability.See details»
Syntis Bio Company Profile 2025: Valuation, Funding
Syntis Bio General Information Description. Developer of a late-stage preclinical platform intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling …See details»
Syntis Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Syntis Bio will initially focus on the development of orally administered therapies for HCU (SYNT-202) and MSUD (SYNT-203), both of which lack approved disease-modifying therapies. ... The …See details»
Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, …
Jun 11, 2024 Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and …See details»
Syntis Bio, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Syntis Bio, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
Syntis Bio - Funding, Financials, Valuation & Investors - Crunchbase
Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Syntis Bio - Updates, News, Events, Signals & Triggers - Crunchbase
Syntis Bio has launched as a clinical-stage biopharmaceutical company focused on developing oral therapies for obesity, diabetes, and rare diseases. The company aims to provide an …See details»
Mussel-Inspired Polymer Helps Syntis Bio Deliver …
Jun 13, 2024 Together, the trio started Syntis Bio—a Dorchester, MA-based company that has raised $15.5 million to date. Syntis Bio’s mission, they say, is to develop oral therapies that provide more ...See details»
Syntis Bio Aims to Transform Oral Therapy for Obesity ... - Patsnap
Jun 17, 2024 Syntis Bio, Inc. has recently emerged as a clinical-stage biopharmaceutical company dedicated to creating oral therapies that aim to provide more accessible, effective, …See details»
Syntis Bio Launches to Develop Therapies for Obesity, Diabetes, …
Jun 11, 2024 Syntis plans to leverage data from this initial study to support its IND application with the U.S. Food and Drug Administration in 2025. SYNT-101 is powered by SYNT …See details»
Contact - Syntis
Reach out at [email protected]. Partnering. We are strategically expanding into therapeutic areas where our evidence-based approach can deliver high value and patient benefit. Externally, we …See details»
Syntis - Biotech Careers
Syntis Bio is unlocking the full therapeutic potential of the small intestine—the body’s nexus for metabolic control, digestion and drug absorption. Business Areas: Small Molecules, MicrobiomeSee details»
Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, …
A formulation of SYNT-101 is currently undergoing human trials to establish preliminary safety, tolerability and blocking efficacy, with a full data readout anticipated by the end of 2024. Syntis …See details»
Syntis Bio - Contacts, Employees, Board Members, Advisors
Syntis Bio has 2 current employee profiles, including Co-Founder, President, CEO Rahul Dhanda. Rahul Dhanda Co-Founder, President, CEO Giovanni Traverso Co-FounderSee details»
Syntis Bio Launches with $15.5M to Tackle Obesity and Rare
Jun 11, 2024 Syntis Bio, Inc. (Syntis) has announced its launch as a clinical-stage biopharmaceutical company dedicated to developing oral therapies that offer more accessible, …See details»
Science - Syntis
Syntis is unlocking the full therapeutic potential of the small intestine—the nexus for metabolic control, digestion and drug absorption. The Body’s Hidden Command Center. The small …See details»
Syntis Bio launches oral therapies for metabolic diseases
Jun 12, 2024 Syntis Bio will initially focus on the development of orally administered therapies for HCU (SYNT-202) and MSUD (SYNT-203), both of which lack approved disease-modifying …See details»
SYNT-101 - Drug Targets, Indications, Patents - Synapse
Syntis Bio will initially focus on the development of orally administered therapies for HCU (SYNT-202) and MSUD (SYNT-203), both of which lack approved disease-modifying therapies. After …See details»